Madison biotechnology company FluGen Inc. will start another round of human trials on its universal flu vaccine next year.

The company recently completed a $5.5 million round of funding to support its continuing research and development.

FluGen’s product, RedeeFlu, is a vaccine to prevent the respiratory illness influenza. The idea behind RedeeFlu is to create a universal flu vaccine that will work year after year.

Read the full story here.